Search results
Results from the WOW.Com Content Network
Jesse Gelsinger (June 18, 1981 – September 17, 1999) was the first person publicly identified as having died in a clinical trial for gene therapy. Gelsinger suffered from ornithine transcarbamylase deficiency , an X-linked genetic disease of the liver , the symptoms of which include an inability to metabolize ammonia – a byproduct of ...
Retinal gene therapy holds a promise in treating different forms of non-inherited and inherited blindness. In 2008, three independent research groups reported that patients with the rare genetic retinal disease Leber's congenital amaurosis had been successfully treated using gene therapy with adeno-associated virus (AAV).
Current Gene Therapy is a peer-reviewed medical journal published by Bentham Science Publishers.The editor-in-chief is Liang Cheng (Harbin Medical University Harbin, China). ). The focus of this journal is pre-clinical or clinical research on gene the
Doheny and USC ended their relationship in 2012, and USC created a new entity called the USC Eye Institute for its department of ophthalmology. [16] In December 2013 the Doheny Eye Institute entered into an exclusive, long-term affiliation agreement with the University of California Los Angeles , [ 17 ] forming the "Doheny Eye Center UCLA".
Translational Genomics Research Institute; California. Clear Labs; Genetic Information Research Institute; Joint Genome Institute (U.S. Department of Energy) Salk Institute for Biological Studies; Illinois. Carl R. Woese Institute for Genomic Biology (University of Illinois, Urbana-Champaign) Maine. The Jackson Laboratory; Maryland. Howard ...
Clinical trials of gene therapy for sickle cell disease were started in 2014. [227] [228] In February LentiGlobin BB305, a gene therapy treatment undergoing clinical trials for treatment of beta thalassemia gained FDA "breakthrough" status after several patients were able to forgo the frequent blood transfusions usually required to treat the ...
The American Glaucoma Society (AGS) is a subspecialty society in ophthalmology that promotes education and research about glaucoma among physicians and scientists. Founded in 1985 by thirteen original members, it now has more than 400 members. The society holds workshops annual meetings. [1] [2]
Animal testing for gene therapy began in 2007 with a 2009 breakthrough in squirrel monkeys suggesting an imminent gene therapy in humans. While progress in gene therapy for red-green color blindness has slowed since then, successful human trials are currently underway for achromatopsia, a different form of color vision deficiency.